Drug Database
Back to search

Netherlands· NL-3a5f967a8f69

Hemgenix 1x10E13 genoomkopieën/ml concentraat voor oplossing voor infusie

A other hematological agents product containing etranacogeen dezaparvovec, registered in Netherlands by CSL Behring GmbH. The same ATC class is registered in 4 of our 19 countries.

ATC B06

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedHemgenix 1x10E13 genoomkopieën/ml con…ATCB06REGISTER NO.NL-3a5f967a8f69PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about etranacogeen dezaparvovecAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Etranacogeen dezaparvovec is registered in 4 of 19 countries.

Countries holding a registration under ATC B06 (other hematological agents), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 1 of them publish a price we can compare per daily dose
Search etranacogeen dezaparvovec products by name

Etranacogeen dezaparvovec · ATC B06

4 / 19 countries

  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ETRANACOGEEN DEZAPARVOVEC
Manufacturer
CSL Behring GmbH
Country
Netherlands (NL)
ATC code
B06
ATC class
OTHER HEMATOLOGICAL AGENTS
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/22/1715

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Etranacogeen dezaparvovec in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All etranacogeen dezaparvovec products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Hemgenix
  • Liechtenstein · Hemgenix
  • Norway · Hemgenix

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9c717346-86f4-467b-8a7e-1d57f3fd1dc5
GET /v1/drugs/9c717346-86f4-467b-8a7e-1d57f3fd1dc5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor injectie of infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/hemgenix-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Other Hematological Agents",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp129771",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
    "KALIUMCHLORIDE (E 508)",
    "KALIUMDIWATERSTOFFOSFAAT 0-WATER (E 340)",
    "NATRIUMCHLORIDE",
    "POLYSORBAAT 20 (E 432)",
    "SACCHAROSE",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "ETRANACOGEEN DEZAPARVOVEC"
  ],
  "leaflet_url": null,
  "authorised_at": "2023/02/20",
  "procedure_number": "EMEA/H/C/004827",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/22/1715",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about etranacogeen dezaparvovec.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console